SCHEDULE 14A INFORMATION

                Proxy Statement Pursuant to Section 14(a) of the
                         Securities Exchange Act of 1934

Filed by the Registrant |_|
Filed by a Party other than the Registrant |X|
Check the appropriate box:

|_| Preliminary Proxy Statement            |_| Confidential, for Use of the
|_| Definitive Proxy Statement                 Commission Only (as permitted by
|_| Definitive Additional Materials            Rule 14a 6(e)(2))
|X| Soliciting Material Pursuant
    to ss.240.14a-11(c) or ss.240.14a-12

                            ICN PHARMACEUTICALS, INC.
- --------------------------------------------------------------------------------
                (Name of Registrant as Specified in its Charter)

                     ICN Committee to Maximize Shareholder Value
- --------------------------------------------------------------------------------
      (Name of Person(s) Filing Proxy Statement, if other than Registrant)

Payment of Filing Fee (Check the appropriate box):

|X|  No fee required

|_|  Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.

     (1) Title of each class of securities to which transaction applies:

         ---------------------------------------------------------------

     (2) Aggregate number of securities to which transaction applies:

         ---------------------------------------------------------------

     (3) Per unit price or other underlying value of transaction computed
         pursuant to Exchange Act Rule 0-11 (Set forth the amount on which the
         filing fee is calculated and state how it was determined:

         ---------------------------------------------------------------

     (4) Proposed maximum aggregate value of transaction:

         ---------------------------------------------------------------

     (5) Total fee paid:

         ---------------------------------------------------------------

|_|  Fee paid previously with preliminary materials.

|_|  Check box if any part of the fee is offset as provided by Exchange Act Rule
     0-11(a)(2) and identify the filing for which the offsetting fee was paid
     previously. Identify the previous filing by registration statement number,
     or the Form or Schedule and the date of its filing.

     (1) Amount previously paid:

     -------------------------------------------------------------------
     (2) Form, Schedule or Registration Statement No.:

     -------------------------------------------------------------------
     (3) Filing Party:

     -------------------------------------------------------------------
     (4) Date Filed:

     -------------------------------------------------------------------





  Response by the ICN Committee to Maximize Shareholder Value to the Statement
             Issued April 3, 2001 by ICN Pharmaceuticals, Inc (ICN)

New York, New York, April 6, 2001/ -- The ICN Committee to Maximize Shareholder
Value regrets the decision by the management of ICN Pharmaceuticals (NYSE: ICN)
to resort to an unfounded personal attack on Dr. Tito Tettamanti, Chairman of
SSP-Special Situations Partners, Inc, which it regards as a distraction from the
serious shareholder issues at hand. The Committee's nominees are individuals of
the highest integrity with extensive business experience and the Committee's
members are interested only in seeking to maximize shareholder value.

The fact that ICN's management has stooped to defamation and intimidation to
discourage the Committee and its nominees from pursuing a legitimate exercise in
corporate democracy merely demonstrates to us management's lack of substantive
arguments to explain the long delay in its promised strategic restructuring.

We cannot help but be struck by the irony that allegations of this nature are
made by a company whose publicly-recorded history (and whose Chairman's history)
shows repeated instances of controversy, lawsuits, investigations, settlements
and consent decrees; a company which, indeed, only days ago announced an
adjustment to its earnings to reflect a $9.25 million reserve in connection with
a pending SEC litigation and grand jury investigation.

Although it goes without saying, the derogatory comments against Dr. Tettamanti
in ICN's April 3rd press release are absurd and completely unfounded.

Mr Milan Panic, Chairman of ICN, is already the subject of a pending criminal
investigation by Swiss judicial authorities following a complaint by Dr.
Tettamanti regarding similar defamatory statements made in January this year.

Enquiries:

Eric Knight

SSP-Special Situations Partners Inc.
Tel. + (377) 93 10 61 40





In connection with its solicitation of proxies with respect to ICN
Pharmaceuticals' 2001 Annual Meeting, the Committee will file with the
Securities and Exchange Commission (the "SEC") and will furnish to security
holders of ICN Pharmaceuticals a proxy statement, which security holders are
advised to read as it will contain important information. Security holders may
obtain a free copy of such proxy statement (when available) and any other
relevant documents filed with the SEC, from the website of the SEC at
www.sec.gov. Copies of any proxy soliciting materials filed by the Committee
with the SEC may also be obtained for free from SSP's website at
www.SSP-specialsituationspartners.com.

The Committee, SSP - Special Situations Partners Inc., Providence Capital, Inc.,
Edward A. Burkhardt, General Ronald R. Fogleman and Steven J. Lee will be (and
certain of the executive officers and directors of SSP and Providence may be)
participants in the solicitation by the Committee of proxies with respect to ICN
Pharmaceuticals' 2001 Annual Meeting. None of such persons has any direct or
indirect interests in the matters to be acted upon at the 2001 Annual Meeting
other than as a stockholder or a nominee for election as a director of ICN
Pharmaceuticals. Further information concerning the participants and their
direct or indirect interests can be found in the Schedule 14A filed pursuant to
Rule 14a-12 with the SEC by the Committee on April 5, 2001.